ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

9 links0 made here, not in the record16 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT01592370An InvestigationalImmuno-Therapy Study toDetermine the Safety andEffectiveness of Nivolumaband Daratumumab in PatientsWith Multiple MyelomaBristol-Myers SquibbPhase 1/Phase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSLymphoma, Non-HodgkinThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionHodgkin DiseaseThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termMultiple MyelomaThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIpilimumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerLirilumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDaratumumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPomalidomideIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDexamethasoneIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Nivolumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Nivolumab”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2NivolumabClaude Opus 5.5TestedCurrent
Nov 2IpilimumabClaude Opus 5.5Background · partnerCurrent
Nov 2LirilumabClaude Opus 5.5BackgroundCurrent
Nov 2DaratumumabClaude Opus 5.5BackgroundCurrent
Nov 2PomalidomideClaude Opus 5.5BackgroundCurrent
Nov 2DexamethasoneClaude Opus 5.5BackgroundCurrent
Nov 14Lymphoma, Non-HodgkinRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Hodgkin DiseaseRule based · condition-kind ruleFinest filed termCurrent
Nov 14Multiple MyelomaRule based · condition-kind ruleFinest filed termCurrent
Nov 18NivolumabRule based · role ruleTestedAgrees
Nov 18IpilimumabRule based · role ruleBackgroundAgrees
Nov 18LirilumabRule based · role ruleBackgroundAgrees
Nov 18DaratumumabRule based · role ruleBackgroundAgrees
Nov 18PomalidomideRule based · role ruleBackgroundAgrees
Nov 18DexamethasoneRule based · role ruleBackgroundAgrees
As of nowLymphoma, Non-HodgkinRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.